{
    "name": "pegfilgrastim",
    "comment": "Rx",
    "other_names": [
        "Neulasta",
        "Fulphila",
        "pegfilgrastim-jmdb",
        "Udenyca",
        "pegfilgrastim-cbqv",
        "Ziextenzo",
        "pegfilgrastim-bmez",
        "pegfilgrastim-apgf",
        "Nyvepria",
        "Fylnetra",
        "pegfilgrastim-pbbk",
        "Stimufend",
        "pegfilgrastim-fpgk"
    ],
    "classes": [
        "Hematopoietic Growth Factors"
    ],
    "source": "https://reference.medscape.com/drug/neulasta-fulphila-pegfilgrastim-342167",
    "pregnancy": {
        "common": [
            "Insufficient data available on use in pregnant women to establish whether there is a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Data from published studies in pregnant women exposed to filgrastim products have not established an association of filgrastim product use during pregnancy with major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "In animal studies, no evidence of reproductive/developmental toxicity occurred in offspring of pregnant rats that received cumulative doses of pegfilgrastim approximately 10 times recommended human dose (based on body surface area); in pregnant rabbits, increased embryolethality and spontaneous abortions occurred at 4 times the maximum recommended human dose simultaneously with signs of maternal toxicity"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown whether pegfilgrastim is secreted in human milk",
            "Other recombinant G-CSF products are poorly secreted in breast milk, and G-CSF is not orally absorbed by neonates",
            "Caution should be exercised when administered to a nursing female"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of serious allergic reactions to pegfilgrastim or filgrastim"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Rare cases of splenic rupture may occur; evaluate if patient experiences left upper abdominal and/or shoulder tip pain",
                "ARDS reported; evaluate symptoms, including fever, pulmonary infiltrates, or respiratory distress; discontinue if ARDS occurs",
                "Serious allergic reactions (eg, anaphylaxis) can occur; majority of reported events occurred upon initial exposure; allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial antiallergic treatment; permanently discontinue treatment in patients with serious allergic reactions (see Contraindications)",
                "Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders; discontinue therapy if sickle cell crisis occurs",
                "Capillary leak syndrome may occur; may vary in frequency and severity; closely monitor patients who develop symptoms and provide standard symptomatic treatment, which may include a need for intensive care",
                "Glomerulonephritis reported; if suspected, evaluate for cause; if causality likely, consider dose reduction or interruption of therapy",
                "Leukocytosis observed; monitoring CBC count during therapy recommended; higher counts reported",
                "Pegfilgrastim may potentially act as growth factor for any tumor type, including myeloid malignancies and myelodysplasia",
                "Missed or partial doses reported in patients receiving drug via OBI due to device not performing as intended; in event of missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if dose had been correctly delivered; instruct patients using OBI to notify their healthcare professional immediately in order to determine need for replacement dose if they suspect that device may not have performed as intended",
                "Aortitis reported; it may occur as early as the first week after start of therapy; manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, C-reactive protein and white blood cell count); consider aortitis in patients who develop these signs and symptoms without known etiology; discontinue if aortitis is suspected",
                "Increased hematopoietic activity of bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes; this should be considered when interpreting bone imaging results",
                "Thrombocytopenia reported; monitor platelet counts",
                "Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) associated with use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer; monitor patients for signs and symptoms of MDS/AML in these settings"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Bone pain",
            "percent": "31"
        },
        {
            "name": "Pain in extremity",
            "percent": "9"
        },
        {
            "name": "Leukocytosis",
            "percent": "100"
        },
        {
            "name": "WBC counts",
            "percent": "10"
        },
        {
            "name": "x",
            "percent": "9"
        },
        {
            "name": "L",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Splenic rupture and splenomegaly",
            "percent": null
        },
        {
            "name": "glomerulonephritis",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorder",
            "percent": null
        },
        {
            "name": "Sickle cell crisis",
            "percent": null
        },
        {
            "name": "leukocytosis",
            "percent": null
        },
        {
            "name": "capillary leak syndrome",
            "percent": null
        },
        {
            "name": "Hypersensitivity Reactions",
            "percent": null
        },
        {
            "name": "Allergic reactions",
            "percent": null
        },
        {
            "name": "hypersensitivity",
            "percent": null
        },
        {
            "name": "including anaphylaxis",
            "percent": null
        },
        {
            "name": "skin rash",
            "percent": null
        },
        {
            "name": "and urticaria",
            "percent": null
        },
        {
            "name": "generalized erythema and flushing",
            "percent": null
        },
        {
            "name": "cutaneous vasculitis to skin",
            "percent": null
        },
        {
            "name": "and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Acute respiratory distress syndrome",
            "percent": null
        },
        {
            "name": "ARDS",
            "percent": null
        },
        {
            "name": "alveolar hemorrhage",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Application site reactions",
            "percent": null
        },
        {
            "name": "application site hemorrhage",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "discomfort",
            "percent": null
        },
        {
            "name": "bruise",
            "percent": null
        },
        {
            "name": "and erythema",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Sweet syndrome",
            "percent": null
        },
        {
            "name": "acute febrile neutrophilic dermatosis",
            "percent": null
        },
        {
            "name": "cutaneous vasculitis",
            "percent": null
        },
        {
            "name": "aortitis",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Contact dermatitis and local skin reactions such as rash",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "and urticaria with on",
            "percent": null
        },
        {
            "name": "body injector",
            "percent": null
        },
        {
            "name": "possibly indicating a hypersensitivity reaction to adhesive",
            "percent": null
        },
        {
            "name": "Myelodysplastic syndrome",
            "percent": null
        },
        {
            "name": "MDS",
            "percent": null
        },
        {
            "name": "and acute myeloid leukemia",
            "percent": null
        },
        {
            "name": "AML",
            "percent": null
        },
        {
            "name": "in patients with breast and lung cancer receiving chemotherapy and",
            "percent": null
        },
        {
            "name": "or radiotherapy",
            "percent": null
        },
        {
            "name": "Injection site reactions",
            "percent": null
        }
    ]
}